Profile data is unavailable for this security.
About the company
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
- Revenue in USD (TTM)362.80m
- Net income in USD-205.49m
- Incorporated2008
- Employees638.00
- LocationBlueprint Medicines Corp45 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 374-7580
- Fax+1 (302) 655-5049
- Websitehttps://www.blueprintmedicines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TG Therapeutics Inc | 346.73m | 95.69m | 3.91bn | 300.00 | 42.08 | 22.02 | 40.79 | 11.27 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 4.22bn | 290.00 | -- | 5.04 | -- | 3,049.44 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Immunovant Inc | 0.00 | -272.55m | 4.23bn | 207.00 | -- | 7.76 | -- | -- | -1.92 | -1.92 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -57.93 | -- | -64.54 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
Arcellx Inc | 144.75m | -53.89m | 4.33bn | 130.00 | -- | 8.87 | -- | 29.91 | -1.05 | -1.05 | 2.84 | 9.08 | 0.2132 | -- | -- | 1,113,423.00 | -7.94 | -38.82 | -9.68 | -45.41 | -- | -- | -37.23 | -339.38 | -- | -- | 0.038 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Denali Therapeutics Inc | 1.27m | -419.65m | 4.40bn | 364.00 | -- | 3.17 | -- | 3,475.74 | -2.85 | -2.85 | 0.0085 | 9.69 | 0.0009 | -- | -- | 2,847.19 | -29.89 | -14.98 | -31.50 | -17.71 | -- | -- | -33,121.86 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Alkermes Plc | 1.51bn | 457.54m | 4.58bn | 2.10k | 10.41 | 3.60 | 9.00 | 3.04 | 2.67 | 1.69 | 8.78 | 7.74 | 0.6864 | 1.31 | 4.28 | 718,055.30 | 20.83 | 1.34 | 26.98 | 1.74 | 83.31 | 83.32 | 30.34 | 2.12 | 2.61 | -- | 0.184 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Madrigal Pharmaceuticals Inc | 14.64m | -510.45m | 5.06bn | 376.00 | -- | 5.90 | -- | 345.85 | -25.50 | -25.50 | 0.7351 | 39.50 | 0.0209 | -- | -- | 38,930.85 | -72.80 | -62.09 | -86.71 | -74.81 | 95.66 | -- | -3,487.13 | -- | 8.67 | -- | 0.1198 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Krystal Biotech Inc | 166.23m | 105.94m | 5.25bn | 229.00 | 50.02 | 6.25 | 46.53 | 31.58 | 3.65 | 3.65 | 5.70 | 29.22 | 0.2076 | -- | -- | 725,908.30 | 13.23 | -11.50 | 14.07 | -12.01 | 93.07 | -- | 63.73 | -492.85 | 9.33 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Ultragenyx Pharmaceutical Inc | 481.30m | -585.12m | 5.32bn | 1.28k | -- | 12.29 | -- | 11.05 | -7.29 | -7.29 | 5.95 | 4.69 | 0.3286 | 1.81 | 5.45 | 377,196.70 | -39.94 | -33.35 | -48.51 | -38.30 | 87.15 | 93.13 | -121.57 | -154.71 | 3.39 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Blueprint Medicines Corp | 362.80m | -205.49m | 5.66bn | 638.00 | -- | 17.62 | -- | 15.60 | -3.42 | -3.42 | 5.85 | 5.07 | 0.3141 | 0.8694 | 5.88 | 553,887.00 | -17.79 | -29.92 | -21.66 | -34.06 | 96.19 | -- | -56.64 | -116.65 | 3.65 | -16.38 | 0.5471 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Cytokinetics, Inc. | 3.13m | -545.28m | 6.58bn | 423.00 | -- | 60.57 | -- | 2,100.15 | -5.37 | -5.37 | 0.0309 | 0.9236 | 0.0027 | -- | 6.36 | 7,408.98 | -47.34 | -43.14 | -51.07 | -47.22 | -- | -- | -17,398.82 | -540.47 | -- | -12.85 | 0.8578 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Ionis Pharmaceuticals Inc | 813.46m | -365.74m | 6.67bn | 927.00 | -- | 23.46 | -- | 8.20 | -2.53 | -2.53 | 5.63 | 1.81 | 0.2873 | 0.4264 | 29.47 | 877,517.80 | -12.92 | -6.30 | -14.43 | -7.44 | 98.58 | 98.75 | -44.96 | -21.23 | 7.51 | -- | 0.8288 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Nuvalent Inc | 0.00 | -173.59m | 6.70bn | 115.00 | -- | 10.43 | -- | -- | -2.78 | -2.78 | 0.00 | 9.84 | 0.00 | -- | -- | 0.00 | -31.08 | -- | -32.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Viking Therapeutics Inc | 0.00 | -96.75m | 7.14bn | 28.00 | -- | 7.75 | -- | -- | -0.9379 | -0.9379 | 0.00 | 8.31 | 0.00 | -- | -- | 0.00 | -14.36 | -21.91 | -14.78 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Revolution Medicines Inc | 742.00k | -519.21m | 7.36bn | 443.00 | -- | 4.51 | -- | 9,918.78 | -3.65 | -3.65 | 0.0051 | 9.77 | 0.0005 | -- | 0.5912 | 1,962.96 | -36.03 | -29.76 | -38.48 | -32.59 | -- | -- | -69,973.99 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 6.35m | 10.03% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 5.79m | 9.14% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 4.75m | 7.51% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 3.96m | 6.25% |
Wellington Management Co. LLPas of 30 Jun 2024 | 3.13m | 4.94% |
Rock Springs Capital Management LPas of 30 Jun 2024 | 2.46m | 3.88% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.38m | 3.76% |
William Blair Investment Management LLCas of 30 Jun 2024 | 1.60m | 2.53% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.46m | 2.30% |
Macquarie Investment Management Business Trustas of 30 Jun 2024 | 1.31m | 2.07% |